Oculis Holding AG Announces Upcoming Investor Conference
Oculis Holding AG (NASDAQ: OCS), a cutting-edge biopharmaceutical company dedicated to enhancing eye health and making strides in ocular science, is gearing up for a noteworthy investor conference. The event promises to showcase the latest developments in their innovative research and product initiatives.
Event Details for Interested Investors
The company has scheduled to present at the renowned Leerink Global Healthcare Conference. This presentation will be delivered by Sylvia Cheung, the Chief Financial Officer of Oculis. Investors can look forward to insights regarding the future direction of Oculis and its impact on eye care.
Presentation Information:
- Date and Time: March 11, 2025, at 3:00 PM ET
- Format: The presentation will cover key aspects of Oculis's product pipeline and strategic vision.
Opportunities for One-on-One Meetings
During the conference, there will also be opportunities for one-on-one meetings. This initiative allows investors to engage directly with Oculis representatives to discuss their interests and inquiries regarding company performance and product advancements. Interested parties are encouraged to reach out to their respective representatives at the sponsoring institution to arrange meetings.
Webcast Access and Further Information
The presentation will also be accessible through a live webcast, providing a convenient way for stakeholders to connect with the company remotely. To access the webcast, investors can visit the Oculis website and navigate to the Events and Presentations section, which will provide more details on how to participate.
About Oculis
Oculis is at the forefront of biopharmaceutical innovation, with a commitment to saving sight and advancing eye care solutions. The company's pipeline is robust, featuring several unique product candidates:
- OCS-01: A topical eye drop for treating diabetic macular edema.
- Privosegtor (OCS-05): A neuroprotective therapy aimed at addressing acute optic neuritis, with potential broader applications in neuro-ophthalmology.
- Licaminlimab (OCS-02): A topical biologic anti-TNF? eye drop designed for patients suffering from dry eye disease.
Oculis operates from its headquarters in Switzerland and has a presence in both the U.S. and Iceland. The company is supported by a team of professionals with extensive experience in the healthcare sector and boasts backing from prominent international healthcare investors.
Contact Information for Oculis
For more inquiries about Oculis and its innovative products, you may reach out to:
Ms. Sylvia Cheung, CFO
Email: sylvia.cheung@oculis.com
Investor and Media Relations
For investor relations, please contact LifeSci Advisors:
Corey Davis, Ph.D.
Email: cdavis@lifesciadvisors.com
Frequently Asked Questions
What is the focus of Oculis Holding AG?
Oculis is dedicated to developing innovative biopharmaceutical solutions aimed at improving eye care and preserving sight.
When is Oculis scheduled to present at the investor conference?
The presentation is slated for March 11, 2025, at 3:00 PM ET.
How can investors participate in the conference?
Investors have the opportunity to attend the conference presentation and can also arrange one-on-one meetings by contacting their institution.
Where can I follow Oculis's live presentation?
The live webcast can be accessed on the Oculis website under the Events and Presentations section.
What are the main product candidates in Oculis's pipeline?
Oculis is developing several candidates, including OCS-01, OCS-05, and OCS-02, each targeting different eye care challenges.